Tag Archive for: enzalutamide

ZZ-FIRST Trial: Adding Talazoparib to Enzalutamide Shows No Clear Additional Benefit in Metastatic Prostate Cancer

/in , , /by

A randomised phase 2 trial published in Nature Medicine has investigated whether adding the PARP inhibitor talazoparib to enzalutamide and androgen deprivation therapy (ADT) can improve outcomes in men with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), regardless of their homologous recombination repair (HRR) mutation status. The study, known as ZZ-FIRST enrolled 54 patients across eight […]

Read more

BUB1B and CENP-E: A New Vulnerability in Enzalutamide-Resistant Prostate Cancer

/in /by

A new preclinical study published in Cancer Research has identified a possible way to attack prostate cancer that has become resistant to castration and enzalutamide. The work focuses on BUB1B, a protein involved in controlling cell division, and CENP-E, one of the proteins it helps regulate. When researchers lowered BUB1B levels, resistant prostate cancer cells […]

Read more

Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC

/in , , , /by

Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a […]

Read more

How Radium‑223 Plus Enzalutamide Accelerates ALP and PSA Responses in Bone‑Metastatic mCRPC

/in /by

An exploratory post hoc analysis of the international PEACE‑3 trial adds a compelling biomarker layer to the already positive story of combining radium‑223 with enzalutamide in men with bone‑metastatic, castration‑resistant prostate cancer. The parent study, a phase 3 randomised trial in asymptomatic or mildly symptomatic metastatic castration‑resistant prostate cancer (mCRPC) with bone metastases, had already […]

Read more

SCD1 Inhibition May Strengthen Enzalutamide Against Resistant Prostate Cancer

/in /by

SCD1 is an enzyme that helps prostate-cancer cells convert saturated fatty acids into monounsaturated fatty acids, which support cell membranes, energy storage and survival signaling. Functional research suggests that some tumors rely on SCD1 activity. Blocking this pathway can disrupt lipid synthesis, androgen-receptor signaling and survival pathways such as AKT. This provides the rationale for […]

Read more

Another Phase 1/2 Trial With SX-682, Combined With Docetaxel This Time

/in , , , /by

SX-682 is moving into a new clinical context. After an ongoing trial in prostate cancer with androgen receptor pathway inhibitors such as apalutamide and enzalutamide, the CXCR1/2 inhibitor is now being studied with docetaxel in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer. That matters because docetaxel is not […]

Read more

Tipifarnib Shows Early Promise as an Adjuvant in Enzalutamide-Resistant Prostate Cancer

/in /by

Tipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, […]

Read more

The MOMENT Trial: Mevrometostat Plus Enzalutamide in Post‑ARPI, Pre‑Abiraterone mCRPC

/in , , /by

Mevrometostat is an oral EZH2 inhibitor being developed to overcome resistance to androgen‑receptor–targeted therapy in prostate cancer. In tumors, EZH2 helps switch off tumor‑suppressor genes and supports androgen‑independent growth and lineage plasticity, changes that are strongly linked to progression on drugs like enzalutamide. Adding an EZH2 inhibitor to continued AR blockade is meant to “re‑discipline” […]

Read more

Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC

/in , , /by

The TALENT trial is a randomized, open‑label, phase 2 trial evaluating whether adding enzalutamide to talazoparib improves outcomes compared with talazoparib alone in men with metastatic castration‑resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) gene alterations and have progressed after abiraterone‑based therapy. The trial builds on the phase 3 TALAPRO‑2 results, which showed […]

Read more

Phase 1/2 Update: Concurrent Enzalutamide–Cabazitaxel Produces Durable PFS Signal in mCRPC

/in , , , /by

The updated Phase 1/2 data for concurrent enzalutamide plus cabazitaxel in chemo‑naïve mCRPC show deep biochemical responses and a promising signal for progression‑free outcomes, but the dataset remains hypothesis‑generating. In a multi‑institutional single‑arm trial of enzalutamide with cabazitaxel (plus prednisone), 35 patients were included in the efficacy analysis with a median follow‑up of 23.7 months; […]

Read more